[1]涂 强.lncRNAs在三阴性乳腺癌发生发展中的作用[J].医学信息,2020,33(10):37-39.[doi:10.3969/j.issn.1006-1959.2020.10.011]
　TU Qiang.The Role of lncRNAs in the Development of Triple Negative Breast Cancer[J].Medical Information,2020,33(10):37-39.[doi:10.3969/j.issn.1006-1959.2020.10.011]
点击复制

lncRNAs在三阴性乳腺癌发生发展中的作用()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年10期
页码:
37-39
栏目:
综述
出版日期:
2020-05-15

文章信息/Info

Title:
The Role of lncRNAs in the Development of Triple Negative Breast Cancer
文章编号:
1006-1959（2020）10-0037-03
作者:
涂 强
（柳州市人民医院肿瘤科，广西 柳州 545006）
Author(s):
TU Qiang
(Department of Oncology,Liuzhou People’s Hospital,Liuzhou 545006,Guangxi,China)
关键词:
三阴性乳腺癌; 长链非编码RNA; 靶向治疗; 耐药性
Keywords:
Triple negative breast cancer; Long non-coding RNA; Targeted therapy; Drug resistance
分类号:
R737.9
DOI:
10.3969/j.issn.1006-1959.2020.10.011
文献标志码:
A
摘要:
乳腺癌是一种发生在乳腺腺上皮组织的一种恶性肿瘤，约占全部乳腺癌的1/5，常见于年轻乳腺癌患者。三阴性乳腺癌相较于其他类型乳腺癌生长迅速，是乳腺癌中预后较差的一个分类。目前，三阴性乳腺癌的特定突变与患者的疾病预后、药物治疗效果的关系尚未明确，导致三阴性乳腺癌一直缺乏有效的生物标志物。近年研究表明长链非编码RNA（lncRNAs）广泛参与基因沉默、转录激活、细胞周期和分化、染色体构型修饰等众多生理功能，成为肿瘤研究领域的新热点。本文就三阴性乳腺癌生物学行为及临床病理特征、lncRNAs概述及其在三阴性乳腺癌发生、发展中的作用作一综述。
Abstract:
Breast cancer is a malignant tumor that occurs in the epithelial tissue of the breast gland, accounting for about 1/5 of all breast cancers, and is common in young breast cancer patients. Compared with other types of breast cancer, triple-negative breast cancer grows rapidly, and it is a classification with poor prognosis in breast cancer. At present, the relationship between specific mutations in triple-negative breast cancer and the patient’s disease prognosis and drug treatment effects is not yet clear, resulting in the lack of effective biomarkers for triple-negative breast cancer. Recent studies have shown that long-chain non-coding RNAs (lncRNAs) are widely involved in many physiological functions such as gene silencing, transcription activation, cell cycle and differentiation, and chromosomal configuration modification, which has become a new hotspot in the field of cancer research. This article reviews the biological behavior and clinicopathological characteristics of triple-negative breast cancer, the overview of lncRNAs, and its effect in the occurrence and development of triple-negative breast cancer.

参考文献/References:

[1]王蔚文.临床疾病诊断与疗效判断标准[M].北京：科学技术文献出版社,2010:1371-1375.[2]许涛,李萍,庞国莲,等.乳腺癌组织miRNAs的异常表达及犀黄丸对体外乳腺癌细胞候选miRNAs的表达影响[J].中国医师杂志,2019,21(7):979-983.[3]张毅,袁梅,刘薇,等.老中青三年龄段三阴性乳腺癌的病理生物学行为及预后影响因素分析[J].中华普通外科杂志,2014,29(11):873-875.[4]Koduru SV,Tiwari AK,Leberfinger A,et al.Abstract 3499:Differentially expressed small noncoding RNAs in triple-negative breast cancer[J].Cancer Res,2017,77(13):3499.[5]付雷,孙琰.伴髓样特征的非特殊型浸润性乳腺癌超声表现1例[J].临床超声医学杂志,2019,21(10):728-728.[6]梁之孔.胶质瘤细胞U87中NSPc1与lncRNAs分子的功能性互作研究[D].河北医科大学,2017.[7]刘艳华,孙三元,鹿存涛.长链非编码RNA在乳腺癌组织与外周血中的表达[J].中华临床医师杂志,2016,10(12):1710-1713.[8]吕明明,许楠,王凤良,等.长链非编码RNA在乳腺癌患者外周血与癌组织中的表达[J].中华乳腺病杂志,2015,9(4):26-30.[9]周洁.动态增强磁共振成像和高频彩超在乳腺癌诊断中的应用比较[J].影像研究与医学应用,2017,1(14):143-144.[10]殷飞,倪毅.长链非编码RNA GAS5在乳腺癌组织中的表达水平及临床意义[J].中国妇幼保健,2018,33(23):5369-5371.[11]熊晶,王渝,王君,等.乳腺癌组织中lncRNA CCHE1水平及其临床意义[J].临床肿瘤学杂志,2018,23(6):519-523.[12]石建国.长链非编码RNA-ROR在肾癌中的表达及临床意义的研究[D].山东大学,2017.[13]Wang SH,Zhang MD,Wu XC,et al.Overexpression of LncRNA-ROR predicts a poor outcome in gallbladder cancer patients and promotes the tumor cells proliferation,migration,and invasion[J].Tumour Biol,2016,37(9):12867-12875.[14]Sun H,Wang G,Peng Y,et al.H19 lncRNA mediates 17beta-estradiol-induced cell proliferation in MCF-7 breast cancer cells[J].Oncol Rep,2015,33(6):3045-3052.[15]张瑞华,劳伟思,许英,等.LncRNA SNHG7通过调控β-catenin蛋白影响乳腺癌细胞的增值、迁移和侵袭[J].岭南现代临床外科,2019,19(1):28-33.[16]Gomez-maldonado L,Tiana M,Roche O,et al.EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination[J].Oncogene,2015,34(20):2609-2620.[17]王远鹤,刘勇,刘飞.lncRNA HOTAIR在胃癌中的表达及对胃癌细胞增殖及自噬的影响[J].解剖科学进展,2019,25(3):289-292.[18]房群.LncRNA UCA1通过下调miR-27b表达增强胃癌多药耐药性的研究[D].山东大学,2017.[19]杨卉.lncRNAs在乳腺癌中的表达及lncMALAT-1对三阴性乳腺癌细胞增殖和侵袭性的影响[D].江苏大学,2018.[20]Jang M,Huang O,Xie Z,et a1.A novel long non-coding RNA-RA:adriamycin resistance-associated[J].Biochem Pharmacol,2014,87(2):254-283．[21]Shi SJ，Wang LJ，Yu B，et al.LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer[J].Oncotarget,2015,6(13):11652-11663.

相似文献/References:

[1]杨宵月,李建伟.LncRNA调控人类疾病关系数据库的研究[J].医学信息,2019,32(12):28.[doi:10.3969/j.issn.1006-1959.2019.12.010]
　YANG Xiao-yue,LI Jian-wei.LncRNA Regulation of Human Disease Relationship Database[J].Medical Information,2019,32(10):28.[doi:10.3969/j.issn.1006-1959.2019.12.010]
[2]张天竺,宁 勇.长链非编码RNA调控乳腺癌发生发展的研究进展[J].医学信息,2019,32(12):40.[doi:10.3969/j.issn.1006-1959.2019.12.014]
　ZHANG Tian-zhu,NING Yong.Advances in Research on Long-chain Non-coding RNA Regulation of Breast Cancer Development[J].Medical Information,2019,32(10):40.[doi:10.3969/j.issn.1006-1959.2019.12.014]
[3]袁晓霞,肖 杨,罗瑶敏,等.长链非编码RNA CASC9的靶基因预测及信号通路富集分析[J].医学信息,2022,35(16):7.[doi:10.3969/j.issn.1006-1959.2022.16.002]
　YUAN Xiao-xia,XIAO Yang,LUO Yao-min,et al.Target Gene Prediction and Signal Pathway Enrichment Analysis of Long Non-coding RNA CASC9[J].Medical Information,2022,35(10):7.[doi:10.3969/j.issn.1006-1959.2022.16.002]
[4]郭居斗,杜振宗,宋剑非.LncRNA作为ceRNA调控miRNA在NSCLC中的作用[J].医学信息,2022,35(15):148.[doi:10.3969/j.issn.1006-1959.2022.15.035]
　GUO Ju-dou,DU Zhen-zong,SONG Jian-fei.The Role of LncRNA as ceRNA in Regulating miRNA in NSCLC[J].Medical Information,2022,35(10):148.[doi:10.3969/j.issn.1006-1959.2022.15.035]
[5]徐忆芳,罗秀丽.基于数据挖掘的罗秀丽教授治疗三阴性乳腺癌的临床经验研究[J].医学信息,2019,32(20):159.[doi:10.3969/j.issn.1006-1959.2019.20.050]
　XU Yi-fang,LUO Xiu-li.Professor Luo Xiuli's Clinical Experience in Treating Triple-negative Breast Cancer Based on Data Mining[J].Medical Information,2019,32(10):159.[doi:10.3969/j.issn.1006-1959.2019.20.050]
[6]贾秀鹏,蒙伶俐,李海莉,等.三阴性乳腺癌与非三阴性乳腺癌组织中PD-1、PD-L1、FOXP3的差异表达及其临床意义[J].医学信息,2021,34(21):7.[doi:10.3969/j.issn.1006-1959.2021.21.002]
　JIA Xiu-peng,MENG Ling-li,LI Hai-li,et al.Differential Expression and Clinical Significance of PD-1, PD-L1 and FOXP3 in Triple-negative Breast Cancer and Non-triple-negative Breast Cancer Tissues[J].Medical Information,2021,34(10):7.[doi:10.3969/j.issn.1006-1959.2021.21.002]
[7]陈晓娆,杨志雄,苏文媚,等.lncRNA在非小细胞肺癌中的研究[J].医学信息,2020,33(12):24.[doi:10.3969/j.issn.1006-1959.2020.12.009]
　CHEN Xiao-rao,YANG Zhi-xiong,SU Wen-mei,et al.Study of lncRNA in Non-small Cell Lung Cancer[J].Medical Information,2020,33(10):24.[doi:10.3969/j.issn.1006-1959.2020.12.009]
[8]张 明.miRNA及lncRNA在糖尿病肾病中的作用机制及临床诊断应用[J].医学信息,2020,33(21):58.[doi:10.3969/j.issn.1006-1959.2020.21.017]
　ZHANG Ming.The Mechanism of miRNA and lncRNA in Diabetic Nephropathy and Clinical Diagnosis Application[J].Medical Information,2020,33(10):58.[doi:10.3969/j.issn.1006-1959.2020.21.017]
[9]张 蕊,耿 佳,王雪梅.长链非编码RNA在内皮细胞损伤模型中的表达调控研究[J].医学信息,2020,33(22):71.[doi:10.3969/j.issn.1006-1959.2020.22.022]
　ZHANG Rui,GENG Jia,WANG Xue-mei.Study on the Expression Regulation of Long Non-coding RNA in Endothelial Cell Injury Model[J].Medical Information,2020,33(10):71.[doi:10.3969/j.issn.1006-1959.2020.22.022]
[10]李阳阳,管 圣.lncRNA调控动脉粥样硬化病变的研究进展[J].医学信息,2021,34(01):49.[doi:10.3969/j.issn.1006-1959.2021.01.014]
　LI Yang-yang,GUAN Sheng.Research Progress in lncRNA Regulation of Atherosclerotic Lesions[J].Medical Information,2021,34(10):49.[doi:10.3969/j.issn.1006-1959.2021.01.014]

更新日期/Last Update: 2020-05-15